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GNE-7915Mutations in PARK8/LRRK2 are the most common genetic cause of Parkinson’s disease. Inhibition of
LRRK2 kinase activity has neuroprotective beneﬁts, and provides a means of addressing the underlying
biochemical cause of Parkinson’s disease for the ﬁrst time. Initial attempts to develop LRRK2 inhibitors
were largely unsuccessful and highlight shortcomings intrinsic to traditional, high throughput screening
methods of lead discovery. Recently, amino-pyrimidine GNE-7915 was reported as a potent (IC50 = 9 nM)
selective (1/187 kinases), brain-penetrant and non-toxic inhibitor of LRRK2. The use of in silico modelling,
extensive in vitro assays and resource-efﬁcient in vivo techniques to produce GNE-7915, reﬂects a trend
towards the concerted optimisation of potency, selectivity and pharmacokinetic properties in early-stage
drug development.
 2013 Elsevier Ltd. All rights reserved.LRRK2 and Parkinson’s disease: Over six million people are cur-
rently living with Parkinson’s disease (PD). It is the second most
common chronic, neurodegenerative disease, affecting 1–2% of
the global population over the age of 65.1 PD is clinically character-
ised by four cardinal symptoms: resting tremor, bradykinesia, pos-
tural instability, and rigidity. The progressive loss of presynaptic
dopaminergic neurons in the substantia nigra pars compacta and
striatum is the dominant neuropathological feature. However,
Lewy bodies, comprised of phosphorylated a-synuclein, tau and
ubiquitin protein aggregates, may also be present.2 PD is treated
symptomatically with dopaminergic or cholinergic modulating
agents, such as levodopa, which was ﬁrst introduced in the early
1960s.3 The continued use of therapeutic agents that cause
signiﬁcant side-effects and lose efﬁcacy with disease progression,underscores the lack of progress in PD pharmacotherapies over
the past 50 years.
The aetiology of PD is a complex interaction between genetics,
age-related physiological changes and/or exposure to environmen-
tal toxins.4 Mutations occurring in seven autosomal genes (PARK1,
2, 5, 6, 7, 8, 9, and 14) have been identiﬁed as PD risk factors. The
clinical phenotype induced by mutation of these genes varies in
terms of severity, genetic penetrance, inheritance pattern and age
of disease onset. PARK1–14 encode a heterogeneous group of pro-
teins ranging from chaperone molecules to various catabolic and
regulatory enzymes.4,5
First cloned in 2004, leucine-rich repeat kinase 2 (LRRK2), is the
gene product responsible for PARK8 (12p11.2-q13.1)-induced neu-
rodegeneration.6 LRRK2 is widely distributed throughout the body
and is found in elevated concentrations in brain, kidney, and heart
tissues, as well as various immune-cell subtypes.6a,7 LRRK2 is a
multi-domain serine-threonine kinase, containing an ATP-utilising
kinase domain, GTPase domain (Ras of complex proteins, ROC), and
several putative protein–protein scaffolding domains, such as the
C-terminal of Roc (COR), leucine-rich repeat (LRR), ankyrin (Ank)
and WD40 domains. Together, these structural features implicate
LRRK2 in a complex array of intracellular processes, the details of
which are described in a recent review by Ray and Liu
M. E. Kavanagh et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3690–3696 3691(Fig. 1).2b,6a,8 Although the endogenous role of LRRK2 remains
unconﬁrmed, ongoing biological studies have identiﬁed a number
of interactions that may be responsible for the pathological effects
of LRRK2 mutants. In the central nervous system (CNS), LRRK2 ap-
pears to induce neuronal apoptosis in a mitochondrial-dependent
fashion by enabling mitochondrial pore formation,9 increasing
the rate of DLP1-dependent mitochondrial ﬁssion,10 and increasing
the production of pro-apoptotic factors, such as caspase 3 and reac-
tive oxygen species (ROS), by inhibition of antioxidant peroxire-
doxin-3.11 LRRK2 was shown to increase the secretion of pro-
inﬂammatory cytokines from immune cells,12 and impede stress
response mechanisms at the level of transcriptional regulation
through phosphorylation of FOXO1 and 4E-BP.13 LRRK2 contributes
to the formation of Lewy body pathology by directly phosphorylat-
ing aggregating proteins and inhibiting the ubiquitin-proteosomal
route of protein clearance.14 Finally, LRRK2 disrupts neuronal mor-
phology,15 vesicular homeostasis,16 and release, recycling and syn-
aptic concentrations of dopamine.17
More than 40 genetic variants of LRRK2 are known, with six
conﬁrmed as pathogenic contributors to PD: G2019S, R1441C/G/
H, Y1699C and I2020T. These mutations are clustered about the
activation loop of the kinase domain, the ROC domain, and also
on the dimerisation interface of the COR domain (Fig. 1).1,18 On
average, the most common variant, G2019S–LRRK2, causes 6% of
all hereditary, and 1–2% of all idiopathic, cases of PD. However,
the prevalence of LRRK2 mutations varies with ethnicity, and
G2019S–LRRK2 is causal in up to 39% of PD cases in North African
Arab populations.1 Due to its prevalence and occurrence in both
hereditary and idiopathic disease subsets, LRRK2 is a valuable tar-
get for elucidating the underlying pathogenic mechanisms of PD.5
LRRK2 as a therapeutic target: In the decade since the implica-
tion of PARK8 in PD, interest in LRRK2 as a potential therapeutic
target has increased exponentially. Over 1700 publications and
94 inhibitor-related patents pertinent to LRRK2 have been pro-
duced since PARK8 was cloned in 2002. Early biochemical charac-
terisation of G2019S–LRRK2 indicated that the mutant protein
has threefold greater catalytic activity than the wild-type (wt)
LRRK2 enzyme,19 and, consequently, LRRK2 inhibitors could repre-
sent a novel therapeutic option for PD.8a Less is known about the
activities of the ﬁve less common LRRK2 mutants which have been
proposed to induce a PD phenotype through alternative mecha-
nisms, such as disrupting GTP-hydrolysis, protein-scaffolding func-
tions or protein stability and dimerisation.8a,19b,20
Comprehensive biochemical analyses and transgenic animal
models provided the initial precedents for the therapeutic beneﬁts
of LRRK2 inhibition. Protein mutation studies conﬁrmed that ki-
nase activity is essential for LRRK2-induced neurotoxicity.19a Ki-
nase-dead LRRK2 mutants (D1994A) ameliorated the phenotypic
cellular changes induced by G2019S–LRRK2, with reduced forma-
tion of Lewy bodies, decreased neurodegeneration and improved
duration of cell survival.20a Conversely, complete knockout of the
PARK8/LRRK2 gene induced histopathological changes to kidney
and lung tissues in mice, and embryonic lethality in zebra ﬁsh.21
These observations suggested that competitive, reversible LRRK21 
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Figure 1. Domain schematic of LRRK2, indicating the six pathinhibitors, rather than irreversible inhibitors or those with a sui-
cide mechanism-of-action, could represent viable therapeutic
compounds for the treatment of PD.
Traditional drug discovery routes: LRRK2 is a challenging target
for traditional methods of drug discovery. The expression and iso-
lation of native LRRK2 is difﬁcult because of its instability and
insolubility.22,23 As such, many studies have focused on developing
recombinant protein constructs and truncated variants in an at-
tempt to mimic structural and functional properties of the endog-
enous protein.8a,19b,20a,22 Current protocols use tagged, full-length
mutant/wt LRRK2 protein expressed in HEK-293 cell lines (or sim-
ilar), or endogenous LRRK2 obtained from Epstein–Barr virus
(EBV)-immortalised lymphoblastoid cells isolated from PD-af-
fected individuals.22,24 The absence of an X-ray crystal structure
of the kinase domain of LRRK2 has forced structure-based drug de-
sign attempts to focus on developing protein homology models for
LRRK2.25 X-ray crystal structures of the ROC domain and the ROC-
COR tandem domain of LRRK2 have been obtained. These struc-
tures provided insight into the disruption of LRRK2 dimerisation
and alteration of GTPase catalytic activity, that is imparted by
pathogenic mutations such as R1441C/G/H.20c,26 More recent stud-
ies have elaborated on the role of GTPase activity in self-regulating
LRRK2 kinase function and highlighted the potential for therapeu-
tic agents targeting the GTPase domain.20b,27
The absence of a conﬁrmed endogenous substrate for LRRK2
necessitated the development of surrogate conditions for assess-
ment of LRRK2 kinase activity. In vitro studies employed the syn-
thetic peptides LRRKtide and Nictide, derived from the moesin–
ezrin–ridixin family of cytoskeletal binding proteins, as surrogate
LRRK2 substrates.25c In vivo analysis of kinase activity relies on
changes in LRRK2 auto-phosphorylation status, or neuronal mor-
phology as a functional measure of activity.15,25c,20a
The combination of these protein constructs and synthetic sub-
strates allowed high throughput screening (HTS) of known kinase
inhibitor libraries to commence in 2009. Initial studies yielded sev-
eral potent, non-selective tool compounds, such as staurosporine
(IC50 = 1–2 nM), sunitinib (IC50 = 15–79 nM), ROCK inhibitor H-
1152 (IC50 = 244 nM), and JAK3 inhibitor VI (IC50 = 22–25 nM),
which are included in a comprehensive review of early LRRK2
inhibitor literature by Kramer et al.,19b,25c,28,29 Analysis of the
structural motifs common to these inhibitors, and the identiﬁca-
tion of kinases sharing a similar inhibitor proﬁle, yielded valuable
information regarding the structure of the LRRK2 active site.25c,28a
This information was used in tandem with protein sequence anal-
ysis to construct in silico kinase homology models for structure-
based drug design.7,25b,30 Analysis of the sensitivity of various
LRRK2 mutants to generic kinase inhibitors highlighted structural
features that may impart drug resistance. For example, the resis-
tance demonstrated by A2016T-LRRK2 suggested that inhibitor
type and/or dose may need to be individualised with respect to pa-
tient genotype if LRRK2 inhibitors are to be implemented as ther-
apeutics for PD.23,25c,28b Generic kinase inhibitors reduced
neurotoxicity and neurodegeneration in animal models of PD,17,31
providing initial proof-of-concept for therapeutic kinase inhibitors.2572 
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to validate the biological response as speciﬁc to LRRK2 inhibition.
Selective LRRK2 inhibitors: The human genome contains over ﬁve
hundred kinases, in addition to other ATP-binding proteins such as
ATPases, adenosine receptors and nucleotide exchange/binding
factors. The ATP-binding site of most kinases is highly conserved,
as are the catalytic amino acid residues involved in the phos-
phoryl-transfer reaction. Consequently, there is limited structural
variation to exploit when designing kinase inhibitors and achieving
selectivity is difﬁcult. Currently marketed kinase inhibitors with
relatively high selectivity achieve this result by exploiting binding
sites present in the kinase inactive (DF(Y)G-out) conformation
(Type-II kinase inhibitors), interacting with allosteric modulatory
sites, or stretching into a hydrophobic pocket adjacent to the
ATP-binding site.32 A series of non-ATP competitive, Type-II kinase
inhibitors have been reported which are active against wt-LRRK2.33
Unfortunately, these compounds lose potency and/or demonstrate
an ATP-competitive mode of inhibition against mutant G2019S–
LRRK2.33a The G2019Smutation has been shown to stabilise the ac-
tive, (DF(Y)G-in) conformation of LRRK2 by enabling additional
hydrogen bonding interactions. This stabilisation may be responsi-
ble for the lower efﬁcacy of Type-II inhibitors against mutant
LRRK2. Consequently, inhibitors which only make contacts with
the allosteric site may not be useful for treating PD caused by
G2019S–LRRK2.8b,23,33a
In the last four years, HTS of diverse chemical libraries has iden-
tiﬁed numerous potent lead scaffolds for the development of
LRRK2 inhibitors, including anilinopyrimidines, pyrazolopyridines
and diazepinones. Derivatisation of these motifs in extensive struc-
ture–activity relationship (SAR) studies has resulted in hundreds of
novel, small molecule LRRK2 inhibitors, with biochemical inhibi-
tory constants (Ki) or half-inhibitory concentrations (IC50) in the
low nanomolar range (<100 nM). The sheer number of compounds
produced highlights the emphasis placed on optimising potency in
early stages of drug discovery. In contrast, the greater resource
intensity involved in optimising selectivity and pharmacokinetics
often relegates consideration of these properties to later phases
of development. The inhibitor selectivity proﬁles were not re-
ported for the majority of the aforementioned compounds.25c,34,35
Two research groups recently reported using high-throughput
kinase proﬁling strategies to identify LRRK2 inhibitors that exhibit
low promiscuity from SAR compound libraries.7,30a Kinase-proﬁl-
ing involves assessing the relative activity and promiscuity of a
compound against a diverse panel of kinases. The technique pro-
vides a parallel approach to determining potency and selectivity
early in the drug discovery process.36 Kinase-proﬁling is valuable
in aiding the interpretation of initial biological screening results
and in enabling compound libraries to be screened with respectN
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Figure 2. Selective or brain-penetrant LRRK2 inhibitors ideto multiple disease targets at one time. This concept is particularly
relevant to kinases, which are increasingly being identiﬁed as po-
tential drug targets for a diverse range of disease states.36 In
2011, Gray and co-workers used three separate kinome-screening
protocols, plus structure-based optimisation steps, to develop the
ﬁrst selective and exceptionally potent (wt-LRRK2 IC50 = 13 nM,
G2019S–LRRK2 IC50 = 6 nM) LRRK2 inhibitor, LRRK2IN1 (Fig. 2,
see Table 1).30a A team from Cellzome, shortly thereafter reported
CZC25146, a similarly potent inihibitor (wt-LRRK2 IC50 = 4 nM,
G2019S–LRRK2 IC50 = 7 nM), which was identiﬁed using a chemical
proteomics screening approach.7 In an analysis of more than 470
kinases, LRRK2IN1 was found to interact with only 12 other ki-
nases, and exhibited sub-micromolar IC50 values at only 5 of
these.38 CZC25146 was found to inhibit just 5 off-target enzymes
when proﬁled against 185 protein kinases and one lipid kinase,
none of which are associated with inhibition-induced toxicity.7,30a
By comparison, the currently marketed ‘selective’ Her2 kinase
inhibitor imatinib inhibits 12 of 317 kinases when evaluated using
similar assays.30a After structural optimisation to maximise po-
tency, the physicochemical and pharmacokinetic parameters of
LRRK2IN1 and CZC25146 were determined. Both LRRK2IN1 and
CZC25146 demonstrated activity in peripheral tissues (kidney
and spleen) when administered in vivo to mice, and show func-
tional neuromodulatory activity in vitro. Despite this initial prom-
ise, neither LRRK2IN1 nor CZC25146 were detected to cross the
blood–brain barrier (BBB) to an appreciable extent. Consequently,
these compounds have not progressed further through preclinical
optimisation.7,30a LRRK2IN1 is currently used as a pharmacological
tool compound to further elucidate the biological role of LRRK2.37
Recently, the previously reported anaplastic lymphoma kinase
(ALK) inhibitor TAE684, and novel compound GSK2578215A, were
identiﬁed as potent LRRK2 inhibitors through HTS of a library of
BBB-penetrable compounds.38 TAE684 and GSK2578215A showed
similar inhibitory activity to LRRK2IN1 and CZC25146 in periphe-
ral tissues, however, neither TAE684 nor GSK2578215A induced
dephosphorylation of LRRK2 in the CNS, despite adequate brain
penetration. In the case of TAE684, reports have suggested that this
may be the result of non-speciﬁc binding interactions.38a The posi-
tive correlation between drug lipophilicity and off-target hydro-
phobic interactions is clearly reﬂected in the calculated octanol–
water partition coefﬁcient (c logP) of TAE684 (c logP = 4.4, Table
1). Similar reasoning may explain the poor activity of
GSK2578215A (c logP = 4.1, Table 1), but this prediction has not
been conﬁrmed.38 Despite inadequate CNS activity, further investi-
gation into GSK2578215A analogues is warranted because its
chemotype is unique within kinase inhibitor literature.39
Predictive structure–property relationship optimisation: Initial
routes to LRRK2 inhibitors emphasised the optimisation of potencyS
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ntiﬁed through HTS and SAR optimisation approaches.
Table 1
Physicochemical and pharmacological properties of LRRK2 inhibitors
Inhibitor c logPa LLE LELP CNS MPO Kib/IC50c (nM) CNS permeability Selectivityg
LRRK2IN1 2.5 5.4 13.0 4.3 6/13 0 12/44230a
CZC25146 2.4 5.9 9.8 3.3 7/75 4%d 5/1857
TAE684 4.4 3.7 22.8 3.1 6/8 1.7e —38a
GSK2578215A 4.1 3.9 15.3 4.0 9/11 1.4e 3/46038b
2 1.8 6.4 5.3 5.5 —/6 — —25b
15 1.7 5.8 5.9 5.4 3/3–2925a,25b,41 0.17f,41 1/45125a, 1/6325b
7 2.1 6.0 7.4 5.1 1/9 0.5f 1/18741
GNE-7915 2.6 5.5 9.9 4.7 1/9 0.5f 1/187, 10/39241
18 1.9 5.6 6.2 5.1 9/28 0.37f 1/18749
a Calculated with ChemDrawUltra v13.
b Biochemical assay, Ki—dissociation constant.
c Biochemical assay, IC50—half-inhibitory concentration.
d Ratio brain:plasma, IV (1 mg/kg), mouse.
e AUCbrain/AUCplasma, IV (1 mg/kg), mouse.
f AUCunbound brain/AUCunbound plasma, IV (0.5 mg/kg), rat.
g Kinases inhibited (excluding LRRK2)/total kinases assayed.
M. E. Kavanagh et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3690–3696 3693using labour and resource-intensive SARs for synthetic derivatisa-
tion. In contrast, there is growing appreciation in the industry for
the early-stage characterisation of pharmacokinetic and physico-
chemical properties, as a means of combating drug attrition during
clinical phases of development. While an ever-increasing number
of in vitro, in vivo and in silico predictive approaches to determin-
ing these parameters are available, a balance must be struck be-
tween speed, resource efﬁciency, and the relevance and quality
of data obtained.40
Estrada et al., illustrated a holistic approach to drug discovery
with the development of the ﬁrst BBB-penetrable, CNS-active,
selective LRRK2 inhibitor, GNE-7915, in late 2012 (Fig. 3).25b,34c,41
GNE-7915 is the product of a structure–property relationship
(SPR) optimisation approach, commencing from HTS hit 2, which
was initially reported by Chen et al., from the same research group
(IC50 = 20 nM, see Table 1).25b In contrast to the previously de-
scribed structure–activity relationship (SAR) approaches, HTS hits
were assessed for their potential as lead scaffolds by comparing
their physicochemical and pharmacokinetic parameters, in addi-
tion to their potency and selectivity. GNE-7915 was equipotent
with previously reported compounds, inhibiting LRRK2 at low
nanomolar concentrations in biochemical (Ki = 1 nM) and cellular
assays (IC50 = 9 nM). GEN-7915 is highly selective across 187
screened kinases, reportedly inhibiting only a single off-target ki-
nase (TTK kinase, IC50 <100 nM). In an extended proﬁle across
392 kinases, GNE-7915 only bound to 10 enzymes to a signiﬁcant
extent (>50% probe displaced at 100 nM). In addition to penetrat-
ing the BBB, GNE-7915 and its progenitors are the ﬁrst selective
LRRK2 inhibitors that have been shown to induce dephosphoryla-
tion of LRRK2 in the brain of transgenic mice. GNE-7915 is not re-
ported to cause cellular or genetic toxicity, and has progressed into
preclinical studies in cynomolgus monkeys.41N
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Figure 3. Derivatives of high-throughput screening hit 2 optimEstrada et al., employed a number of physicochemical property-
based scoring systems as initial in silico screening parameters to
improve the synthetic efﬁciency of their optimisation process en
route to GNE-7915.25b,41 Since the advent of Lipinski’s rule of ﬁve
in 1995,42 numerous algorithms and optimal value ranges have
been proposed as guidelines for hit-to-lead optimisation. These
scoring functions aim to reduce attrition during clinical phase drug
development by using physicochemical properties as predictors of
drug pharmacokinetic and safety proﬁles. Improved binding po-
tency has been found to strongly correlate with increased molecu-
lar weight (MW) and lipophilicity (c logP).43 However, these
physicochemical properties are also closely aligned with poor
CNS permeability, reduced safety thresholds and increased binding
promiscuity.44 Ligand efﬁciency (LE), lipophilic ligand efﬁciency
(LLE) and ligand-efﬁciency-dependent lipophilicity (LELP), are
three recently described scoring functions that attempt to normal-
ise for these effects by penalising MW and lipophilic contributions
to drug potency.43,45 Owing to their ease of application and gener-
ality, these parameters have rapidly gained acceptance in industry,
and were used in the optimisation GNE-7915 from hit 2.25b,41
LE provides a measure of drug binding or potency per heavy
atom (Eq. 1).45a Hit 2 (LE = 0.34, Table 1) complies with the sug-
gested minimum LE of 0.3 for hit compounds, which was calcu-
lated to allow sufﬁcient scope to increase MW over drug
optimisation whilst remaining within Lipinski’s guidelines (MW
<500 Da).45b LLE prioritises compounds whose lipophilic contribu-
tion to potency is low (Eq. 2).43 The LLE values calculated in Table 1
closely comply with mean values for lead compounds (LLE 3.8) or
marketed drugs (LLE = 5–6.2).44b,46 The lower LLE of TAE684 and
GSK2578215A suggests lipophilicity contributes disproportion-
ately to their binding activity. Scoring functions which optimise
potency with respect to a single physicochemical parameter, suchN
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Figure 4. Docking image of 1525b (cyan) in the ATP-binding site of a JAK2-derived
LRRK2 homology model (green).41 Key predicted binding interactions between
anilino-pyrimidine and kinase hinge residues (Glu1948 and Ala 1950) are shown in
yellow. The JAK2 selectivity residue (Leu1949? Tyr908) is shown in magenta,
limiting the bulk of the aniline 2C-methoxy substituent. Image adapted and
reprinted with permission from Estrada et al., J. Med. Chem. 2012, 55, 9416.
Copyright 2012, American Chemical Society
3694 M. E. Kavanagh et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3690–3696as LE and LLE, often show little reproducibility when making com-
parisons between different drug targets or chemotypes.45c LELP
combines both MW and lipophilicity into a single scoring term as
a way to improve versatility and predictive power (Eq. 3).45c Lower
absolute values (10 < LELP < 10) reﬂect properties more closely
aligned with marketed drugs or lead compounds, which have mean
LELP scores of 6.4 and 11, respectively.44b Two recent analyses of
ligand efﬁciency parameters as applied to marketed drugs and
their corresponding leads, supported the greater predictive power
of combined scoring functions such as LELP. Both studies con-
cluded that only LELP was capable of distinguishing between mar-
keted drugs and unsuccessful lead compounds, and that while all
three ligand efﬁciency parameters were useful during the initial
stages of drug development, LELP correlated with safety and phar-
macokinetic proﬁling most strongly.44b,46 The amino-pyrimidine
series (2, 15, 7, GNE-7915) described by Estrada et al., were all cal-
culated to have LELP values within the expected range for lead
compounds (Table 1).41 In contrast, compounds with low CNS per-
meability, or weaker pharmacokinetic and safety proﬁles such as
LRRK2IN1, CZC25146, GSK2578215A and TAE684 had higher LELP
scores. Notably, the high LELP scores calculated for TAE684 and
GSK2578215A, compounds which are known to cross the BBB,
indicates that LELP cannot be used as a direct measure of brain per-
meability. Rather, LELP provides a quantitative measure of the con-
tributions of both MW and lipophilicity to drug activity.
LE ¼ pKiorpIC50
#heavy atoms
ð1Þ
LLE ¼ pK iðor pIC50  c log Pðorc logDÞÞ ð2Þ
LELP ¼ c log Pðorc logDÞ
LE
ð3Þ
Extending the concept of incorporating multiple physicochem-
ical parameters into a single scoring function, Wager et al., recently
developed a CNS multi-parameter optimisation (MPO) algorithm
which was shown to give robust correlations in more than thirty
recent studies.47 The CNS MPO algorithm includes weighted com-
ponents (score 0–1) for six physicochemical parameters: MW,
c logP, calculated distribution coefﬁcient at pH 7.4 (c logD), topo-
logical polar surface area (tPSA), number of hydrogen bond donors
(HBD) and ionisation constant of the most basic functional group
(pKa). The values are combined in an additive manner, which max-
imises design ﬂexibility, removes hard cut-off values for individual
parameters and recognises that different combinations of proper-
ties may result in a similar biological proﬁle. A high CNS MPO score
(0–6) is correlated with important pharmacokinetic properties,
such as increased passive permeability across the BBB, reduced
transporter (P-glycoprotein, P-gp)-mediated efﬂux, reduced intrin-
sic clearance of the unbound drug and improved cell viability in
toxicity studies.47 The CNS MPO scores calculated for LRRK2 inhib-
itors (Table 1) are in accordance with the majority (74%) of mar-
keted CNS-active drugs (CNS MPO P4) or drug candidates.47
These scores reﬂect favourable properties reported by Estrada et
al., including high passive permeability and low P-gp efﬂux. While
the CNS MPO scores in Table 1 do not directly correlate with re-
ported CNS permeability, compounds with higher scores show
greater alignment of favourable drug-like properties. The low
CNS MPO score calculated for brain penetrant compound TAE684
(CNS MPO = 3.1, Table 1) falls within an expected margin of er-
ror.38a,47 Analysis of 119 marketed CNS drugs found that 26% had
CNS MPO scores less than or equal to that of TAE684. While suc-
cessfully passing clinical trials, these drugs with low CNS MPO
scores were signiﬁcantly more likely to suffer from low passive
permeability, high P-gp efﬂux, rapid clearance or cellular toxicity
than drugs with high CNS MPO scores (>5).47The variation in ligand efﬁciency scores in Table 1 from those
previously reported in the literature reﬂect the different software
suites used to calculate physicochemical properties.25b,41 Variation
in the algorithms encoded, input parameters, methods of energy
minimisation and compound training sets employed by software
will alter predicted values. As such, direct comparisons should only
be made between values calculated using the same software.48
Notably, owing to the incorporation of multiple predicted parame-
ters and the data transformation involved in calculating CNS MPO
scores, these values varied minimally between different software
suites, which supports the versatility of this optimisation
parameter.
After employing in silico predictors to select synthetic targets
with high potential for CNS activity, Estrada et al., employed a rel-
atively resource-efﬁcient cassette-dosing approach to determine
in vivo pharmacokinetic data. cassette-dosing was originally de-
scribed in 1997,50 but its application to CNS drugs was only re-
cently justiﬁed by Liu et al.,51 cassette-dosing involves
administering multiple drugs in a single dose to an animal, often
at low concentrations (1–3 mg/kg) to prevent competition at the
BBB. Pharmacokinetic parameters may then be determined from
area-under-the-curve (AUC) calculations. Combining this in vivo
data with in vitro measures of percentage brain/plasma protein
binding and hepatic clearance allowed Estrada et al., to minimise
synthetic efforts and make rationally justiﬁed structural
modiﬁcations.
Structure-based drug optimisation: Chen et al., used protein
sequencing and homology modelling approaches to introduce ra-
tional modiﬁcations to the scaffold of hit 2.25b In the absence of a
crystal structure of the LRRK2 kinase domain, Chen et al., con-
structed a homology model based on the co-crystal structure of Ja-
nus kinase 2 (JAK2, Fig. 4).25b Protein-sequence alignment of the
ATP-binding site was employed to identify four amino acid resi-
dues (Phe1883, Leu1949, Ser1954 and Arg1957) that showed low
conservation across the kinome and were in close proximity to
the docked inhibitor. In silico matched-pair analysis of screened
compound libraries was used to identify molecular substituents
conferring an activity or potency ‘cliff’, and could therefore be
modiﬁed to engender inhibitor selectivity. These two approaches
were combined to produce intermediate 7, differing from 2 by
the introduction of a 3-methoxy group to the benzamide ring
and substitution of the 5-chloro group of the pyrimidine with a tri-
ﬂuoromethyl unit. These changes successfully improved selectivity
M. E. Kavanagh et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3690–3696 3695over all but 1 (TTK, IC50 <0.1 lM) of 180 other kinases screened,
thereby supporting the rapid, inexpensive and synthetically efﬁ-
cient methods employed.41
In contrast, a secondary attempt by Estrada et al., to abrogate
the predicted genotoxic cross-reactivity of 7 with TTK kinase using
the same strategy was, in our opinion, unsuccessful.41 Compound 7
was modiﬁed by extension of the pyrimidine 4C-alkylamine and
substitution of a 5C-ﬂuoro group on the benzamide ring to give
lead compound GNE-7915. The 5C-ﬂuoro-substituent was incorpo-
rated into the scaffold of 7 to provide steric repulsion from the
bulky aspartate residue (D608) found in TTK kinase. These struc-
tural alterations were effective in decreasing binding afﬁnity for
TTK kinase (Ki (7) = 26 nM, Ki (GNE-7915) = 52 nM), but did not
cause a measurable change in functional inhibition of either LRRK2
(IC50 = 9 nM) or TTK kinase (IC50 <100 nM) in vitro. This example
highlights that binding afﬁnity does not directly correlate with
functional activity, and that utilisation of binding, functional and
cellular assays is important to drug discovery and development.
While in vivo selectivity may be improved by either increasing
afﬁnity for the desired target or decreasing off-target afﬁnity, the
identical functional activity of 7 and GNE-7915, and minimal
change in binding afﬁnity for LRRK2 (Ki (7) = 2 nM, Ki (GNE-
7915) = 1 nM), suggests that decreased cross reactivity with TTK
kinase is unlikely to be responsible for the improved safety proﬁle
of GNE-7915. Instead, structural modiﬁcations may have concom-
itantly reduced the toxicological proﬁle of GNE-7915 serendipi-
tously. It is therefore possible, that other compounds overlooked
by Estrada et al., in this study, due to their lower in vitro TTK/
LRRK2 selectivity ratios, could be as successful in vivo as GNE-
7915.
Since the publication of GNE-7915, amino-pyrazole analogue 18
was developed to address the limited solubility and poor metabolic
proﬁle shared by the majority of the aniline-containing compounds
described above.49 This work, carried out by the same group that
developed GNE-7915, describes the use of oxidation-resistant bio-
isosteres and in silico docking studies to increase aqueous solubil-
ity 20-fold over the respective aniline analogues, and remove the
potential for toxic ortho-quinolone biotransformation. While this
result is commendable, and was achieved with minimal synthetic
effort through the use of predictive scoring functions and early
stage in vitro and in vivo pharmacokinetic analysis, 18 trails
GNE-7915 in the majority of other relevant properties. Neverthe-
less, while the pyrazole functionality has been previously identi-
ﬁed in HTP screening studies, 18 is the ﬁrst compound of its
class that is potent, selective, and CNS-active, making it a valuable
contribution to the ﬁeld of LRRK2 kinase inhibitors.34j,52
Outlook and summary: While this article emphasises the impor-
tance of selectivity, recognition of the beneﬁts of moderately pro-
miscuous drugs is undergoing resurgence in the industry.53 The
ability to shut down multiple signalling routes at once, prevents
redundancy in drug action, and may also reduce the risk of resis-
tance mechanisms arising from point mutations in the target mol-
ecule.54 Inhibitors which are non-selective between mutant LRRK2
isoforms, or which also inhibit other kinase pathways implicated in
may beneﬁt a greater proportion of the PD-affected population. As
opposed to absolute selectivity, trends are now moving towards
considering the biological relevance of promiscuity, and redirect-
ing efforts towards reducing interactions with known toxicity tar-
gets.32 While in vitro assessment of hERG channel inhibition is
considered mandatory for pre-clinical drug assessment, evidence
indicates that analysis across a broader range of potential toxicity
targets in early-phase drug development may improve success
rates in clinical trials.40
Biological studies continue to elucidate the complexity of
LRRK2-mediated signalling and importance of LRRK2 to cellular
maintenance. LRRK2 is widely distributed in both the CNS andperiphery, and its ubiquity is consistent with the detrimental ef-
fects arising from both increased and decreased LRRK2 activ-
ity.37b,55 The therapeutic index of LRRK2 inhibitors remains to be
demonstrated in the clinic, and may ultimately determine the suc-
cess of this approach for treating PD.
While GNE-7915 is considered the leading candidate LRRK2
inhibitor for potential progression to clinical trials, Kim et al., re-
cently reported a BBB-penetrable LRRK2 inhibitor, G-969 (struc-
ture undisclosed), with excellent potency and moderate
selectivity for LRRK2.56 A number of recent patent applications
from the same research group as Kim et al., detail pyrazolo-pyrim-
idine and pyramidone-type compounds with moderate potency
and functional activity.34h,57 The exponential rise in interest into
LRRK2-targetting therapeutics, and shift towards concerted opti-
misation of drug-like properties, suggests that many compounds
with similar potency and CNS activity to GNE-7915 can be ex-
pected in the near future.
The need for new PD therapeutics capable of modifying disease
progression, rather than providing acute symptomatic relief, is
increasing with the aging global population. Mutations of LRRK2
are implicated in disease processes, and proof-of-principle studies
have demonstrated the potential therapeutic beneﬁts of inhibiting
LRRK2 kinase activity. The successful development of potent, selec-
tive and CNS active LRRK2 inhibitors, such as GNE-7915, suggests
that PD treatments exploiting this novel mechanism of action
could appear in clinical trials in the near future. More importantly,
the diverse strategies used to develop the compounds highlighted
in this article signify a shift in the traditional paradigm of medici-
nal chemistry. Hopefully further consideration of biologically rele-
vant physicochemical parameters in early-stage drug development
will reduce rates of attrition during clinical trials and expedite the
route for novel pharmaceutics to enter the market.References and notes
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